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Abstract
Background and Objectives
Anti-hypertensive treatment with the angiotensin II receptor antagonist olmesartan is a rare
cause of severe Sprue-like enteropathy. To substantiate the hypothesis that olmesartan
interferes with gut immune homeostasis, clinical, histopathological and immune features
were compared in olmesartan-induced-enteropathy (OIE) and in autoimmune enteropathy
(AIE).
Methods
Medical files of seven patients with OIE and 4 patients with AIE enrolled during the same
period were retrospectively reviewed. Intestinal biopsies were collected for central histo-
pathological review, T cell Receptor clonality and flow cytometric analysis of isolated intesti-
nal lymphocytes.
Results
Among seven olmesartan-treated patients who developed villous atrophy refractory to a
gluten free diet, three had extra-intestinal autoimmune diseases, two had antibodies react-
ing with the 75 kilodalton antigen characteristic of AIE and one had serum anti-goblet cell
antibodies. Small intestinal lesions and signs of intestinal lymphocyte activation were thus
reminiscent of the four cases of AIE diagnosed during the same period. Before olmesartan
discontinuation, remission was induced in all patients (7/7) by immunosuppressive drugs.
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After interruption of both olmesartan and immunosuppressive drugs in six patients, remis-
sion was maintained in 4 but anti-TNF-α therapy was needed in two.
Conclusion
This case-series shows that olmesartan can induce intestinal damage mimicking AIE. OIE
usually resolved after olmesartan interruption but immunosuppressive drugs may be neces-
sary to achieve remission. Our data sustain the hypothesis that olmesartan interferes with
intestinal immuno regulation in predisposed individuals.
Introduction
Olmesartan is an angiotensin II receptor antagonist used to treat arterial hypertension. Several
cases of chronic diarrhea with weight loss, anaemia and low serum albuminemia have been
reported after the use of olmesartan [1]. The Mayo Clinic was the first to report 22 cases of
severe Sprue-like enteropathy associated with olmesartan [2]. All patients displayed villous
atrophy and 14/22 had intraepithelial hyperlymphocytosis. Together with the high frequency
of HLA-DQ2 genotype (present in 68%), these features were reminiscent of celiac disease.
However no serum anti-transglutaminase antibodies (in absence of IgA and IgG deficiency)
were detected and none of the patients responded to a gluten-free diet. Notably, three of them
had detectable serum anti-enterocyte antibodies. In another series of 72 patients with unex-
plained intestinal villous atrophy and negative celiac serology, 16 cases were ascribed to the
use of olmesartan [3]. More recently a French National cohort study reported 36 cases of
olmesartan-induced enteropathy (OIE), 32/36 of which had villous atrophy. None had
serum anti-transglutaminase or anti-enterocyte antibodies but 9/11 had anti-nuclear antibod-
ies [4]. The mechanisms underlying duodenal villous atrophy and intraepithelial hyperlym-
phocytosis (65% of cases) [1], remain elusive. Cell-immunity mediated damage is suggested by
the long delay between the onset of olmesartan therapy and the development of enteropathy
with diarrhea [2]. The present examination of clinico-pathological features and phenotypic
characterization of intestinal lymphocytes in seven patients with OIE eliminated other causes
of severe enteropathies, notably common variable immunodeficiency and refractory celiac dis-
ease but revealed striking similarities with four cases of adult autoimmune enteropathy (AIE)
referred to our institution during the same period. Moreover all OIE patients responded to
immunosupressive drugs before olmesartan discontinuation and anti-TNF- therapy was neces-
sary to maintain or achieve remission in 2 out of 6 patients after olmesartan interruption.
Methods
Patients
Medical files of patients treated with olmesartan and presenting severe enteropathy (patients
1–7) and of patients with autoimmune enteropathy (AIE) (patients 8–11) were reviewed retro-
spectively. Patients were followed-up until June 2014. Onset of lymphoma in AIE patient 9 and
patient 10 was previously reported [5, 6].
Material & Methods
Clinical data recorded for each patient included age, sex, symptoms, and body mass index
(BMI). Presence of anti-AIE-75KD antibodies, anti-nuclear and anti-tissue antibodies (anti-
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mitochondria, -LKM1, -smooth muscle, -thyroid) and serological tests of celiac disease (serum
immunoglobulin IgA (AGA) and IgG (AGG) anti-gliadin antibodies, serum IgA class endomy-
sial antibodies (EMA), serum anti-human tissue transglutaminase IgA (tTG) antibodies) were
also recorded. HLA-DRB1 and DQB1 genotyping was performed by hybridization with
sequence-specific oligonucleotides following amplification by PCR, using the InnoLipa HLA
genotyping test (Abott, Rungis France) [7]. Endoscopic evaluation included upper gastrointes-
tinal endoscopy or enteroscopy with gastric and small intestinal biopsies, colonoscopy with
colonic biopsies. Clinical response was defined by a reduction of 50% of stool frequency and
recovery of at least 50% of body weight loss. Mucosal response was defined by total or partial
recovery of a normal villous epithelium [8].
For histological analysis, gastrointestinal specimens were fixed in 10% formalin, embedded
in paraffin, and 5 μm sections stained with H&E and Giemsa. Villous atrophy was assessed on
two to 3 duodenal biopsies as described [9]. Duodenal lymphocytosis was defined by counts of
intraepithelial lymphocytes (IEL) over 30 per 100 duodenal epithelial cells (EC), lymphocytic
gastritis by IEL counts over 25 per 100 gastric columnar EC and lymphocytic colitis by IEL
counts over 20 per 100 surface colonic EC. Apoptotic bodies (single-cell karyorrhectic debris)
were assessed and were enumerated per 10 crypts [9].
Isolation of IEL, lamina propria lymphocytes (LPL) and peripheral blood lymphocytes
(PBL) was performed as described [8, 10, 11]. Surface Lymphocyte phenotype was assessed by
8-color flow-cytometry. Briefly, pellets of 2-5x104 cells were incubated for 20 minutes with
mixof antibodies directly conjugated with FITC, APC, PE, PE/Cy7 BD-Horizon-V450, PerCP/
Cy5.5, AmCyan, APC-H7 at optimal concentrations. The following antibodies were used:
CD45, CD3, CD4, CD8, NKP46, CD56, CD57, NKG2A, control isotypes (BD Biosciences, Le
Pont de Claix, France), CD103, NKG2C, CD94, TCRαβ, TCRγδ (Beckman Coulter, Nyon,
Switzerland) and NKG2C (R&D system, Abingdon, UK). For intracellular FOXP3 detection,
cells were surface labeled with CD45, CD4 and CD25, and then fixed, permeabilized using
Human FOXP3 Buffer Set (BD Biosciences) and labelled with PE-conjugated anti-human or
control isotype (BD Biosciences). Fluorescence staining was analyzed with a FACSCanto II
flow cytometer using the DIVA software (BD Biosciences) and gated on CD45+ cells.
Molecular detection of clonal TCRγ chains rearrangements was performed on DNA
extracted from frozen specimens and from PBL by multiplex PCR and confirmed by analysis
of heteroduplex formation, as described [8].
Ethics Statement
The study was approved by the Ile-de-France II ethical committee (Paris, France).
Results
Clinical and immunological characteristics (Table 1)
Seven patients treated by olmesartan were referred to our medical center between 2000 and
2014 for unexplained severe enteropathy with villous atrophy refractory to a gluten free diet
(Table 1). All had chronic diarrhea with malnutrition. Four of them (patients 1, 2, 4 and 5)
were treated by parenteral nutrition at time of admission and two patients had already been
hospitalized for severe hypokalemia (patients 1 and 4). Three patients had extra-
intestinal autoimmune diseases. Four patients had the celiac HLA-DQ2/DQ8 susceptibility
genotype. Celiac antibodies (IgA and IgG anti-gliadin and anti-transglutaminase, IgA anti-
endomysium) were tested before initiating a gluten free diet and were negative except in one
HLA-DQ2 patient (patient 1) who had low titers of serum IgA anti-
transglutaminase (Table 1). Primary immunoglobulin deficiency was eliminated in all patients.
Olmesartan Enteropathy
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Serum antibodies reacting with goblet cells or with the brush border 75-kilodalton antigen
(AIE-75KD) were detected in one (1/4) and 2 patients (2/6), respectively. Serum anti-
nuclear antibodies were detected in 4 patients (4/5).
Histopathological findings (Fig 1)
Duodenal or jejunal biopsies showed subtotal (patients 2, 3 and 7) or total villous atrophy
(patients 1,4, 5 and 6), dense lymphocyte and plasma cell lamina propria infiltration and crypt
rarefaction (patients 1–7), paucity of goblet cells and glandular apoptosis (patients 2 and 4).
Such intestinal pathological features were reminiscent of those observed in 4 patients with
adult autoimmune enteropathy (AIE) investigated during the same period (Fig 1). An intestinal
collagenous subepithelial layer thicker than 10μmwas observed in patient 1, as in one AIE
patient (patient 9). Patient 4 had very high numbers of IEL in the duodenum (100%) and dis-
played lymphocytic gastritis. Similarly, two AIE patients (9 and 10) with increased numbers of
duodenal IEL also had lymphocytic gastritis and/or colitis (Table 1).
Lymphocyte isolation and flow cytometry analysis (Tables 2, 3 and 4)
Yield of isolated IEL was low or normal in all patients with OIE and AIE (0.1–0,3x106/6
duodenal biopsies) except for patient 11 with AIE complicated by a CD4+ lymphoma which
infiltrated the gut epithelium. In contrast, and in keeping with lamina propria infiltration in
tissue sections, the yield of LPL was increased (0,8 à 1.5x106/ 6 duodenal biopsies, normal 0.5
±0.1). Flow cytometry analysis showed a predominance of CD3+ TCRαβ+T cells in IEL and
Table 1. Clinical and immune characteristics.
Case Sex Age
(y)
Autoimmunediseases BMI DQ2/
8
Anti AIE
75 kDa
anti-
E
tTG IGA ANA Duod Lymphocytosis
Duod Sto Col
Olme-
sartan
1 F 74 Goujerot Sjogren 17 + + nd + - + TVA 30% - -
2 F 72 - 23 nd + nd - - nd STVA 40% - -
3 F 69 Uveitis Cholangitis 17 + - - - nd + STVA 40% - -
4 M 79 - 20 + - - - nd + TVA 30% - -
5 M 60 - 21 - - - - nd - TVA 100% + -
6 F 65 Cholangitis 20 - - nd - - + TVA 30% - -
7 M 77 - 24 + nd -* - - nd STVA 30% - -
Mean 71 20 67% 33% 0% 14% 0% 80% 43% 14% 0
AIE
8 F 17 Auto I Pancreatitis anti-
phospholipid Sd Polyarthritis
16 + + nd - - + TVA 40% - -
9 F 23 - 21 - + + - - + TVA 90% + +
10 F 19 - 20 - + - + - nd STVA 57% - +
11 F 41 - 18 - + nd + + + STVA 65% - -
Mean 25 25% 19 25% 100% 50% 50% 25% 100% 63% 25% 50%
*: detection of serum anti-goblet cells antibodies.
Ab: antibody. Anti-E: anti-enterocyte Ab. ANA: anti-nuclear Ab. BMI: Body Mass Index. Col: colon. Duod: duodenum. EMA: IgA anti-endomysium. IGA: IgA
anti-gliadin. Lymphocytosis: number of intraepithelial lymphocytes for 100 epithelial cells. LC: lymphocytic colitis. LG: lymphocytic gastritis. Sto: stomach.
tTG: IgA anti-transglutaminase. VA: villousatrophy. TVA: total villousatrophy. ST VA: sub-totalvillousatrophy. PVA: partial villousatrophy. y: years.
Noserum anti-tTG IgG or antigliadin IgG was found. No IgA anti-endomysium was found.
doi:10.1371/journal.pone.0125024.t001
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LPL. In contrast with observations in celiac disease, the frequency of γδT IEL was low in both
OIE and AIE, while the frequency of CD4+ IEL was often high in OIE. A very high count of
CD4+ IEL cells was observed in patient 10, who had AIE complicated by a CD4+small cell T
lymphoma which infiltrated the epithelium. In some OIE and AIE patients, T cells expressing
the CD57 or NKG2C NKmarkers were increased in epithelium and lamina propria, suggesting
chronic activation. Interestingly, the frequency of the normal subset of IEL lacking surface
CD3 and expressing the NK marker NKP46 was higher in patients with OIE than with AIE
(Table 2), even if the difference was not statistically significant. The frequency of CD3- IEL
remained however within normal values, thus eliminating type II refractory CD (Tables 2 and
3) [10]. No deficit in the number of intestinal and blood regulatory T cells CD4+CD25
+FOXP3+ was found either in OIE or in adult AIE (Tables 3 and 4). No clonal rearrangement
of T cell receptor gamma was found in intestinal mucosa of patients treated with olmesartan,
while two out of four adult AIE displayed either an oligoclonal (patient 9) or clonal (patient 11)
repertoire [5,6].
Fig 1. H&E staining of the duodenal biopsies of one patient treated with Olmesartan (patient 2) (A, B) and of one patient with AIE (patient 7) (C, D)
showing subtotal villous atrophy (A, C: original magnification x 100) with glandular apoptosis (B, D: original magnification x200).
doi:10.1371/journal.pone.0125024.g001
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Outcome of olmesartan-induced enteropathy (Table 5)
Patients were treated with olmesartan for 2 to 10 years at a mean dosage of 20mg/day at onset
of diarrhea. Following diagnosis of villous atrophy resistant to a gluten free diet, they received
steroids and immunosuppressors (Table 5). In all but one (patient 4), steroids and immuno-
suppressors were introduced before olmesartan discontinuation (Table 5). Treatment with
anti-TNF-αantibodies induced clinical response in 5 patients (5/6) with partial villous recovery
Table 2. Phenotype of intestinal intraepithelial lymphocytes.
Case CD103+ CD8+ CD4+ TCR CD94+ CD56+ CD57+ NKP46 NKG2A NKG2C
CD3+ CD3- αβ γδ
Olmesartan
1 71% 2% 67% 30% 86% 5% 20% - 3% 3% 5% 5%
2 60% 21% 63% 23% 74% 3% - 44% - 26% - 10%
3 69% 23% 64% 11% 59% 12% 27% 37% 16% 37% 17% 3%
4 83% 5% 66% 35% 92% 2% 46% 5% 18% 6% 5% 8%
5 47% 30% 54% 19% 64% 6% 20% 10% 24% 35% 7% 80%
6 53% 14% 46% 29% 72% 4% 16% 11% 9% 12% 10% 7%
Median 65% 17% 64% 26% 73% 4% 20% 11% 16% 19% 7% 7%
AIE
8 71% 5% 70% 24% 85% 2% 64% 22% 2% 6% 5% 80%
9 79% 1% 80% 4% 95% 3% 27% 3% 10% - - -
10 88% 4% 90% 4% 94% 0% 8% 6% 7% 1% - -
11 93% 3% 40% 60%* 88% 8% 13% 2% 1% 7% 4% 5%
Median 84% 4% 75% 14% 91% 3% 20% 5% 5% 6% 4% 48%
Normal value (%) 80–95 2–20 60–85 5–15 70–88 12–20 16–38 9–19 0 5–15 11–38 1–5
*: excess of CD4+ IEL with onset of CD4 lymphoma after two years treatment with azathioprine (Case published in Malamut et al, ClinGastHepatol 2014);
ﬂow cytometry analysis of AIE onset is not available.
doi:10.1371/journal.pone.0125024.t002
Table 3. Phenotype of lamina propria intestinal lymphocytes.
Case CD103+ CD3+ CD103- CD3+ CD8+ CD4+ TCR alpha
beta
CD19+ CD94+ CD56+ CD57+ NKG2C CD4+ CD25+
FOXP3+
Olmesartan
1 34% 52% 35% 53% 80% 8% 3% - 1% 3% 5%
2 25% 53% 50% 45% 74% - - 42% - 6% 6%
3 28% 62% 39% 51% 84% 8% 12% 5% 10% - 6%
4 23% 66% 38% 56% 85% 8% 17% 1% 11% 1% 11%
5 42% 39% 47% 38% 73% 8% 3% 5% 30% 17% 4%
6 26% 52% 37% 39% 68% 23% 10% 2% 9% 5% 10%
Median 27% 53% 39% 48% 77% 8% 10% 5% 10% 5% 6%
AIE
8 23% 49% 40% 38% 73% 18% 24% 14% 5% 3% 8%
9 54% 45% 55% 38% - - - - - - 4%
10 38% 57% 47% 49% 94% 5% 7% 6% 8% - 8%
11 38% 75% 33% 54% 83% 1% 27% 10% 5% 16% 1%
Median 38% 53% 43% 44% 83% 5% 24% 10% 5% 10% 6%
Normal Value (%) 20–35 40–70 30–50 40–60 65–85 5–10 <8 <10 <1 <0,5 2–12
doi:10.1371/journal.pone.0125024.t003
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in 3 patients (3/6). FK-506 and rapamycin were used in patient 1, who had collagenous-
like sprue and induced complete clinical and histological recovery with disappearance of the
collagenous subepithelial layer. After olmesartan discontinuation, remission was maintained
despite withdrawal of immunosuppressive drugs in patients 1, 2, 5 and 6. Complete mucosal
recovery was confirmed on control intestinal biopsies performed 2 to 7 months later and these
patients remain in clinical remission at latest follow-up, one year after cessation of immuno-
suppression interruption. Patient 4 had stopped olmesartan six months before admission as
hypertension had resolved because of the severe diarrhea. Despite this, diarrhea persisted, with
important potassium loss that required intravenous supplementation and prolonged hospitali-
zation. Steroids given intravenously were inefficient but infusion of anti-TNF-αantibodies
Table 4. Phenotype of peripheral blood lymphocytes.
Case CD103+ CD3- CD3+ CD8+ CD3+ CD4+ TCR alpha beta CD19+ CD94+ CD56+ CD57+ NKG2C LT CD4+ CD25+
FOXP3+
Olmesartan
1 0.5% 10% 49% - 11% - - - - 3%
2 0.5% 8% 63% 69% - - 52% - - 5%
3 0.1% 25% 50% 71% 17% 15% 13% 16% - 3%
4 0.1% 13% 62% - 30% - - - 1% 4%
5 - 19% 47% - 6% - - - 6% 6%
6 0.1% 37% 39% 81% 8% - 8% 16% 0% 1%
Median 0.1% 16% 50% 71% 11% 15% 13% 16% 1% 4%
AIE
8 0.0% 34% 39% 68% 7% 23% 57% 31% 73% 4%
9 0.4% 38% 50% - - 30% 20% 26% - -
10 0.0% 30% 61% 87% 4% 6% 11% 19% - 4%
11 0.2% 22% 61% 78% 1% 12% 5% 13% 3% 3%
Median 0.1% 32% 55% 78% 4% 17% 16% 23% 38% 4%
Normal Value (%) <1 30–50 40–60 65–85 5–20 5–25 5–25 5–25 0 2–12
doi:10.1371/journal.pone.0125024.t004
Table 5. Treatments.
Steroids AZA/6MP Anti-TNF-α Cyclosporin Rapamycin FK-506 Rituximab
Olmesartan
1 10 m:-/ - 4m:-/- 1 m:-/- - 2m: +/+ 8m: +/+ -
2 12m: +/+ 6m:-/nd 30 m: +/- - - - -
3 6m: +/ nd 48 m: +/nd - - - - -
4 2 m:-/nd - 12m: +/+ - - - -
5 1m:-/nd - 6m: +/- - - - -
6 12m: +/nd 12m: +/nd 12m: +/+ - - 1m:-/nd -
7 12m: +/+ - 12m: +/+ - - - -
AIE
8 2m:-/- 1m:-/- 9m:-/- 36m: +/+ - - -
9 47m: +/+ 114m: +/- 2m:-/- - - - 1m:-/-
10 15m:-/ nd 2m:-/nd 10 m: +/- 12m: +/+ - - nd
11 6m:-/nd 14m: +/+ - - - - 1m:-/-
m: month. AZA: azathiopurin. 6MP: 6 mercaptopurin. clinical response (+ or-) / mucosal effect (+/-)
doi:10.1371/journal.pone.0125024.t005
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rapidly induced clinical remission. Mucosal healing was observed after seven months of treat-
ment and no relapse was observed after two years without any immunosuppressive treatment.
Patient 7 was already treated with anti-TNF-α at time of olmesartan interruption. Despite
olmesartan discontinuation, diarrhea relapsed after anti-TNF-α withdrawal but remission was
restored when anti-TNF-αtherapy was resumed. Three months after olmesartan discontinua-
tion, he is still treated with anti-TNF-α. Despite being informed of the risks, patient 3 has not
stopped olmesartan and still needs azathioprine to control diarrhea.
Discussion
During the past three years, several cases of severe enteropathy were described in association
with olmesartan [2, 12]. A recently published six year-review of pathology reports of patients
investigated in the US showed no association between the use of olmesartan and the histologi-
cal diagnosis of celiac disease or microscopic colitis, respectively [13] suggesting that this severe
gastrointestinal disorder is a rare adverse effect of this angiotensin receptor-blocker. Our obser-
vations further suggest that OIE affects predisposed individuals. As already reported by Rubio-
Tapia, we observed an increased prevalence of the HLA-DQ2/DQ8 genotype (67%), which pre-
disposes to celiac disease or to type I diabetes. In support of our hypothesis, extra-intestinal
autoimmune diseases were found in 3/7 patients.
The olmesartan prodrug is converted within the small bowel into olmesartan medoxomil,
the active compound, which binds the angiotensin 2 receptor AT1 [14, 15, 16]. How olmesar-
tan can induce severe inflammation and intestinal damage remains to be elucidated. In keeping
with the hypothesis of an immune mechanism, OIE referred to our institution shared striking
similarities with AIE. In both situations, severe villous atrophy was associated with glandular
apoptotic lesions and increased numbers of intestinal T cells expressing the NK markers CD57
or NKG2C. Antinuclear and anti-AIE-75KD or anti-goblet cells antibodies were found in
respectively 80% and 43% of patients. Moreover, all patients with OIE responded to immuno-
suppressive drugs. Cases of patients 4 and 7 are particularly informative, as anti-TNF-α ther-
apy was necessary to achieve remission of a self-sustaining enteropathy after olmesartan
discontinuation. It suggests that olmesartan could trigger immune-mediated enteropathy, a
hypothesis in line with the inhibitory effects of the angiotensin receptor blockers on transform-
ing growth factor beta, an immunoregulatory cytokine necessary for gut immune homeostasis
[17]. Interestingly, cases of enteropathy related to other angiotensin II receptor inhibitors seem
to be much less frequent than OIE [4]. The selective role of olmesartan might be explained by
its conversion into the active form in the intestine, its long half-life and its efficacy, 30 fold
higher than that of other sartans.
Altogether these data support caution when using olmesartan in patients with an autoim-
mune background.
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